Chemical Probes for Histamine Receptor Subtypes.

Histamine / pharmacology Histamine Antagonists / chemistry Ligands Receptors, Histamine
Fluorescence Histamine Histamine H1 receptor Histamine H2 receptor Histamine H3 receptor Histamine H4 receptor PET Radioligands

Journal

Current topics in behavioral neurosciences
ISSN: 1866-3370
Titre abrégé: Curr Top Behav Neurosci
Pays: Germany
ID NLM: 101535383

Informations de publication

Date de publication:
2022
Historique:
pubmed: 2 10 2021
medline: 1 10 2022
entrez: 1 10 2021
Statut: ppublish

Résumé

Ligands with different properties and different selectivity are highly needed for in vitro and in vivo studies on the (patho)physiological influence of the chemical mediator histamine and its receptor subtypes. A selection of well-described ligands for the different receptor subtypes and different studies is shown with a particular focus on affinity and selectivity. In addition, compounds with radioactive or fluorescence elements will be presented with their beneficial use for other species or different investigations.

Identifiants

DOI: 10.1007/7854_2021_254 PMID: 34595743
pubmed: 34595743
doi: 10.1007/7854_2021_254
doi:

Substances chimiques

Histamine Antagonists 0
Ligands 0
Receptors, Histamine 0
Histamine 820484N8I3

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

29-76

Informations de copyright

© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.

Références

Adami M, Micheloni C, Grandi D, Stark H (2018) Differential effects of functionally different histamine H4 receptor ligands on acute irritant dermatitis in mice. Naunyn Schmiedebergs Arch Pharmacol 391:1387–1397
pubmed: 30145688 doi: 10.1007/s00210-018-1553-x
Akdis CA, Blaser K (2003) Histamine in the immune regulation of allergic inflammation. J Allergy Clin Immunol 112:15–22
pubmed: 12847474 doi: 10.1067/mai.2003.1585
Al-Damluji S, Porter D, Krsmanovic LZ, Knutson JR, Kopin IJ (1997) Visual detection of transport-P in peptidergic neurones. Br J Pharmacol 120:876–882
pubmed: 9138694 pmcid: 1564534 doi: 10.1038/sj.bjp.0700970
Alewijnse AE et al (1998) Constitutive activity and structural instability of the wild-type human H2 receptor. J Neurochem 71:799–807
pubmed: 9681472 doi: 10.1046/j.1471-4159.1998.71020799.x
Altenbach RJ et al (2008) Structure–activity studies on a series of a 2-aminopyrimidine-containing histamine H4 receptor ligands. J Med Chem 51(20):6571–6580
pubmed: 18811133 doi: 10.1021/jm8005959
Andaloussi M et al (2013) A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: comparison of hERG binding and target residence time with PF-3893787. Bioorg Med Chem Lett 23:2663–2670
pubmed: 23558237 doi: 10.1016/j.bmcl.2013.02.091
Angeli A, Ferraroni M, Supuran CT (2018) Famotidine, an antiulcer agent, strongly inhibits helicobacter pylori and human carbonic anhydrases. ACS Med Chem Lett 9:1035–1038
pubmed: 30344913 pmcid: 6187404 doi: 10.1021/acsmedchemlett.8b00334
Arrowsmith CH et al (2015) The promise and peril of chemical probes. Nat Chem Biol 11:536–541
pubmed: 26196764 pmcid: 4706458 doi: 10.1038/nchembio.1867
Ashworth S et al (2010) Evaluation of11C-GSK189254 as a novel radioligand for the H 3 receptor in humans using PET. J Nucl Med 51:1021–1029
pubmed: 20554726 doi: 10.2967/jnumed.109.071753
Auerbach S. DrugMatrix/ToxFX. https://ntp.niehs.nih.gov/data/drugmatrix/ . Assessed May 2021
Bahi A, Sadek B, Schwed SJ, Walter M, Stark H (2013) Influence of the novel histamine H3 receptor antagonist ST1283 on voluntary alcohol consumption and ethanol-induced place preference in mice. Psychopharmacology (Berl) 228:85–95
doi: 10.1007/s00213-013-3019-7
Barbier AJ et al (2004) Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H 3 antagonist. Br J Pharmacol 143:649–661
pubmed: 15466448 pmcid: 1575430 doi: 10.1038/sj.bjp.0705964
Bardgett ME, Davis NN, Schultheis PJ, Griffith MS (2011) Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APPTg2576 mouse model of Alzheimer’s disease. Neurobiol Learn Mem 95:64–72
pubmed: 21073971 doi: 10.1016/j.nlm.2010.10.008
Bartole E et al (2020) UR-DEBa242: a Py-5-Labeled fluorescent multipurpose probe for investigations on the histamine H3 and H4 receptors. J Med Chem 63:5297–5311
pubmed: 32420741 doi: 10.1021/acs.jmedchem.0c00160
Baumeister P et al (2015) [3H]UR-DE257: development of a tritium-labeled squaramide-type selective histamine H2 receptor antagonist. ChemMedChem 10:83–93
pubmed: 25320025 doi: 10.1002/cmdc.201402344
Bäumer W et al (2011) Lack of preventing effect of systemically and topically administered histamine H 1 or H 4 receptor antagonists in a dog model of acute atopic dermatitis. Exp Dermatol 20:577–581
pubmed: 21521369 doi: 10.1111/j.1600-0625.2011.01268.x
Bautista-Aguilera ÓM et al (2017) Multitarget-directed ligands combining cholinesterase and monoamine oxidase inhibition with histamine H3R antagonism for neurodegenerative diseases. Angew Chem Int Ed 56:12765–12769
doi: 10.1002/anie.201706072
Bautista-Aguilera ÓM et al (2018) Contilisant, a tetratarget small molecule for Alzheimer’s disease therapy combining cholinesterase, monoamine oxidase inhibition, and H3R antagonism with S1R Agonism profile. J Med Chem 61:6937–6943
pubmed: 29969030 doi: 10.1021/acs.jmedchem.8b00848
Berg KA, Clarke WP (2018) Making sense of pharmacology: inverse agonism and functional selectivity. Int J Neuropsychopharmacol 21:962–977
pubmed: 30085126 pmcid: 6165953 doi: 10.1093/ijnp/pyy071
Bergman J, Spealman RD (1986) Some behavioral effects of histamine H1 antagonists in squirrel monkeys. J Pharmacol Exp Ther 239:104–110
pubmed: 2876090
Best CH, Dale HH, Thorpe WV (1927) The nature of the vaso-dilator constituents of certain tissue extracts. J Physiol 62:397–417
pubmed: 16993860 pmcid: 1514980 doi: 10.1113/jphysiol.1927.sp002369
Bhowmik M, Saini N, Vohora D (2014) Histamine H3 receptor antagonism by ABT-239 attenuates kainic acid induced excitotoxicity in mice. Brain Res 1581:129–140
pubmed: 24952295 doi: 10.1016/j.brainres.2014.06.012
Bitner RS, Markosyan S, Nikkel AL, Brioni JD (2011) In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer’s disease. Neuropharmacology 60:460–466
pubmed: 21044639 doi: 10.1016/j.neuropharm.2010.10.026
Black JW, Ganellin CR (1974) Naming of substituted histamines. Experientia 30:111–113
doi: 10.1007/BF01921632
Bosma R, Mocking TAM, Leurs R, Vischer HF (2017) Ligand-binding kinetics on histamine receptors. https://doi.org/10.1007/978-1-4939-6843-5_5
Boyle DL et al (2019) Toreforant, an orally active histamine H 4 -receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate: mechanism of action results from a phase 2, multicenter, randomized, double-blind, placebo-controlled synovial biopsy study. Inflamm Res 68:261–274
pubmed: 30739130 doi: 10.1007/s00011-019-01218-y
Buckland J (2013) Experimental arthritis: antihistamines as treatments for autoimmune disease? Nat Rev Rheumatol 9:696
pubmed: 24166240 doi: 10.1038/nrrheum.2013.169
Buckland KF, Williams TJ, Conroy DM (2003) Histamine induces cytoskeletal changes in human eosinophils via the H 4 receptor. Br J Pharmacol 140:1117–1127
pubmed: 14530216 pmcid: 1574117 doi: 10.1038/sj.bjp.0705530
Bunnage ME, Chekler ELP, Jones LH (2013) Target validation using chemical probes. Nat Chem Biol 9:195–199
pubmed: 23508172 doi: 10.1038/nchembio.1197
Cao X et al (2018) Synthesis and biological evaluation of fused tricyclic heterocycle Piperazine (Piperidine) derivatives as potential multireceptor atypical antipsychotics. J Med Chem 61:10017–10039
pubmed: 30383372 doi: 10.1021/acs.jmedchem.8b01096
Capelo R et al (2016) Cellular analysis of the histamine H4 receptor in human myeloid cells. Biochem Pharmacol 103:74–84
pubmed: 26774453 doi: 10.1016/j.bcp.2016.01.007
Cataldi M, Maurer M, Taglialatela M, Church MK (2019) Cardiac safety of second-generation H1-antihistamines when updosed in chronic spontaneous urticaria. Clin Exp Allergy 49:1615–1623
pubmed: 31519068 doi: 10.1111/cea.13500
Clapham J, Kilpatrick GJ (1994) Thioperamide, the selective histamine H3 receptor antagonist, attenuates stimulant-induced locomotor activity in the mouse. Eur J Pharmacol 259:107–114
pubmed: 7957603 doi: 10.1016/0014-2999(94)90498-7
Corcóstegui R, Labeaga L, Innerárity A, Berisa A, Orjales A (2005) Preclinical pharmacology of bilastine, a new selective histamine H 1 receptor antagonist: receptor selectivity and in vitro antihistaminic activity. Drugs R D 6:371–384
pubmed: 16274260 doi: 10.2165/00126839-200506060-00005
Coruzzi G et al (2011) Selective histamine H 3 and H 4 receptor agonists exert opposite effects against the gastric lesions induced by HCl in the rat stomach. Eur J Pharmacol 669:121–127
pubmed: 21839070 doi: 10.1016/j.ejphar.2011.07.038
Cowden JM, Zhang M, Dunford PJ, Thurmond RL (2010) The histamine H4 receptor mediates inflammation and pruritus in Th2-dependent dermal inflammation. J Invest Dermatol 130:1023–1033
pubmed: 19907432 doi: 10.1038/jid.2009.358
Cowden JM et al (2014) The histamine H4 receptor mediates inflammation and Th17 responses in preclinical models of arthritis. Ann Rheum Dis 73:600–608
pubmed: 24126456 doi: 10.1136/annrheumdis-2013-203832
Dale HH, Laidlaw P (1910) The physiological actions of b-imidazol ethylamine. J Physiol 41:318–344
pubmed: 16993030 pmcid: 1512903 doi: 10.1113/jphysiol.1910.sp001406
Daley-Yates P et al (2012) The efficacy and tolerability of two novel H 1/H 3 receptor antagonists in seasonal allergic rhinitis. Int Arch Allergy Immunol 158:84–98
pubmed: 22212854 doi: 10.1159/000329738
Day M et al (2007) Differential effects of ciproxifan and nicotine on impulsivity and attention measures in the 5-choice serial reaction time test. Biochem Pharmacol 73:1123–1134
pubmed: 17214974 doi: 10.1016/j.bcp.2006.12.004
Deml KF, Beermann S, Neumann D, Strasser A, Seifert R (2009) Interactions of histamine H1-receptor agonists and antagonists with the human histamine H4-receptor. Mol Pharmacol 76:1019–1030
pubmed: 19720730 doi: 10.1124/mol.109.058651
Desmadryl G et al (2012) Histamine H 4 receptor antagonists as potent modulators of mammalian vestibular primary neuron excitability. Br J Pharmacol 167:905–916
pubmed: 22624822 pmcid: 3575788 doi: 10.1111/j.1476-5381.2012.02049.x
Díaz NF, Flores-Herrera H, Molina-Hernández A (2019) Central histamine, the H3-receptor and obesity therapy. CNS Neurol Disord Drug Targets 18:516–522
pubmed: 31269888 doi: 10.2174/1871527318666190703094846
Di Carlo G et al (2000) Effect of R-(-)-alpha-methylhistamine and thioperamide on in vivo release of norepinephrine in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 24:275–284
pubmed: 10800750 doi: 10.1016/S0278-5846(99)00093-7
Dunford PJ et al (2007) Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus. J Allergy Clin Immunol 119:176–183
pubmed: 17208599 doi: 10.1016/j.jaci.2006.08.034
Dyhrfjeld-Johnsen J, Attali P (2019) Management of peripheral vertigo with antihistamines: new options on the horizon. Br J Clin Pharmacol 85:2255–2263
pubmed: 31269270 pmcid: 6783586 doi: 10.1111/bcp.14046
Eissa N et al (2018) The histamine H3 receptor antagonist DL77 ameliorates MK801-induced memory deficits in rats. Front Neurosci 12:1–11
doi: 10.3389/fnins.2018.00042
Eissa N et al (2021) The multi-targeting ligand ST-2223 with histamine H 3 receptor and dopamine D 2/D 3 receptor antagonist properties mitigates autism-like repetitive behaviors and brain oxidative stress in mice. Int J Mol Sci 22:1947
pubmed: 33669336 pmcid: 7920280 doi: 10.3390/ijms22041947
Elz S, Gerhard G, Schunack W (1989) Histamine analogues. 32nd communication: synthesis and pharmacology of sopromidine, a potent and stereoselective isomer of the achiral H2-agonist impromidine. Eur J Med Chem 24:259–262
doi: 10.1016/0223-5234(89)90007-X
Elz S et al (2000) Histaprodifens: synthesis, pharmacological in vitro evaluation, and molecular modeling of a new class of highly active and selective histamine H1-receptor agonists. J Med Chem 43:1071–1084
pubmed: 10737740 doi: 10.1021/jm991056a
Engelhardt H, Smits RA, Leurs R, Haaksma E, De Esch IJP (2009) A new generation of antihistamines: histamine H4 receptor antagonists on their way to the clinic. Curr Opin Drug Discov Devel 12:628–643
pubmed: 19736622
Ennis M, Tiligada K (2021) Histamine receptors and COVID-19. Inflamm Res 70:67–75
pubmed: 33206207 doi: 10.1007/s00011-020-01422-1
Esbenshade TA et al (2012) Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther 343:233–245
pubmed: 22815533 doi: 10.1124/jpet.112.194126
Faghih R et al (2002) Structure-activity relationships of non-imidazole H3 receptor ligands. Part 2: binding preference for D-amino acids motifs. Bioorg Med Chem Lett 12:2035–2037
pubmed: 12113836 doi: 10.1016/S0960-894X(02)00310-4
Fox GB et al (2002) Effects of histamine H3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav Brain Res 131:151–161
pubmed: 11844582 doi: 10.1016/S0166-4328(01)00379-5
Fox GB et al (2003) Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J Pharmacol Exp Ther 305:897–908
pubmed: 12606600 doi: 10.1124/jpet.102.047241
Fox GB et al (2005) Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl] ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 r. J Pharmacol Exp Ther 313:176–190
pubmed: 15608077 doi: 10.1124/jpet.104.078402
Freedberg DE et al (2020) Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study. Gastroenterology 159:1129–1131.e3
pubmed: 32446698 doi: 10.1053/j.gastro.2020.05.053
Frye SV (2010) The art of the chemical probe. Nat Chem Biol 6:159–161
pubmed: 20154659 doi: 10.1038/nchembio.296
Funke U et al (2013) 11C-labeled and 18F-labeled PET ligands for subtype-specific imaging of histamine receptors in the brain. J Label Compd Radiopharm 56:120–129
doi: 10.1002/jlcr.3038
Galeotti N, Sanna MD, Ghelardini C (2013) Pleiotropic effect of histamine H4 receptor modulation in the central nervous system. Neuropharmacology 71:141–147
pubmed: 23583928 doi: 10.1016/j.neuropharm.2013.03.026
Galici R et al (2011) JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology (Berl) 214:829–841
doi: 10.1007/s00213-010-2092-4
Garbarg M, Arrang J-M, Rouleau A, Ligneau X, Dam Trung Tuong M, Schwartz JC, Ganellin CR (1992) S-[2-(4-Imidazolyl)ethyl]isothiourea, a highly specific and potent histamine H3 receptor agonist. J Pharmacol Exp Ther 263:304–310
pubmed: 1383495
Gbahou F, Rouleau A, Arrang J-M (2012) The histamine autoreceptor is a short isoform of the H3 receptor. Br J Pharmacol 166:1860–1871
pubmed: 22356432 pmcid: 3402810 doi: 10.1111/j.1476-5381.2012.01913.x
Ghamari N et al (2019) Histamine H3 receptor antagonists/inverse agonists: where do they go? Pharmacol Ther 200:69–84
pubmed: 31028835 doi: 10.1016/j.pharmthera.2019.04.007
Grätz L et al (2020) NanoBRET binding assay for histamine H2 receptor ligands using live recombinant HEK293T cells. Sci Rep 10:1–10
doi: 10.1038/s41598-020-70332-3
Gschwandtner M, Stark H, Gutzmer R (2013) Profiling of histamine H 4 receptor agonists in native human monocytes. Br J Pharmacol 170:136–143
pubmed: 23638754 pmcid: 3764855 doi: 10.1111/bph.12237
Guo RX et al (2009) Differential effects of acute and repeat dosing with the H 3 antagonist GSK189254 on the sleep-wake cycle and narcoleptic episodes in Ox−/− mice. Br J Pharmacol 157:104–117
pubmed: 19413575 pmcid: 2697793 doi: 10.1111/j.1476-5381.2009.00205.x
Gutzmer R et al (2009) The histamine H4 receptor is functionally expressed on TH2 cells. J Allergy Clin Immunol 123:619–625
pubmed: 19281909 doi: 10.1016/j.jaci.2008.12.1110
Haas HL, Sergeeva OA, Selbach O (2008) Histamine in the nervous system. Physiol Rev 88:1183–1241
pubmed: 18626069 doi: 10.1152/physrev.00043.2007
Hair P, Scot L (2006) Levocetirizine. Drugs 66
Hancock AA et al (2004) Antiobesity effects of A-331440, a novel non-imidazole histamine H 3 receptor antagonist. Eur J Pharmacol 487:183–197
pubmed: 15033391 doi: 10.1016/j.ejphar.2004.01.015
Hancock AA et al (2005) Antiobesity evaluation of histamine H3 receptor (H3R) antagonist analogs of A-331440 with improved safety and efficacy. Inflamm Res 54:45–47
doi: 10.1007/s00011-004-0412-z
Hartwig C et al (2015) The histamine H
pubmed: 25501767 doi: 10.1002/eji.201445179
Hirschfeld J et al (1992) Iodoaminopotentidine and related compounds: a new class of ligands with high affinity and selectivity for the histamine H2 receptor. J Med Chem 35:2231–2238
pubmed: 1613748 doi: 10.1021/jm00090a013
Holgate ST et al (2003) Consensus group on new-generation antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 33:1305–1324
pubmed: 12956754 doi: 10.1046/j.1365-2222.2003.01769.x
Hough LB et al (1988) Actions of the brain-penetrating H2-antagonist zolantidine on histamine dynamics and metabolism in rat brain. Biochem Pharmacol 37:4707–4711
pubmed: 3202904 doi: 10.1016/0006-2952(88)90341-3
Hu W, Chen Z (2017) The roles of histamine and its receptor ligands in central nervous system disorders: an update. Pharmacol Ther 175:116–132
pubmed: 28223162 doi: 10.1016/j.pharmthera.2017.02.039
Humbert-Claude M, Davenas E, Gbahou F, Vincent L, Arrang JM (2012) Involvement of histamine receptors in the atypical antipsychotic profile of clozapine: a reassessment in vitro and in vivo. Psychopharmacology (Berl) 220:225–241
doi: 10.1007/s00213-011-2471-5
Igel P, Dove S, Buschauer A (2010) Histamine H4 receptor agonists. Bioorg Med Chem Lett 20:7191–7199
pubmed: 21044842 doi: 10.1016/j.bmcl.2010.10.041
Ishiwata K, Kawamura K, Yanai K, Harry Hendrikse N (2007) In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J Nucl Med 48:81–87
pubmed: 17204702
Ishola AA et al (2021) Molecular basis for the repurposing of histamine H2-receptor antagonist to treat COVID-19. J Biomol Struct Dyn:1–18
Istyastono E et al (2011) Molecular determinants of ligand binding modes in the histamine H4 receptor: linking ligand-based 3D-QSAR models to in silico guided receptor mutagenesis studies. J Med Chem 54:8136–8147
pubmed: 22003888 doi: 10.1021/jm201042n
Jablonowski JA et al (2003) The first potent and selective non-imidazole human histamine H4 receptor antagonists. J Med Chem 46:3957–3960
pubmed: 12954048 doi: 10.1021/jm0341047
Jansen FP et al (1994) Characterization of the binding of the first selective radiolabeled histamine H3-receptor antagonist, [125I]-iodophenpropit, to rat brain. Br J Pharmacol 113:355–362
pubmed: 7834183 pmcid: 1510107 doi: 10.1111/j.1476-5381.1994.tb16995.x
Jansen FP, Mochizuki T, Yamamoto Y, Timmerman H, Yamatodani A (1998) In vivo modulation of rat hypothalamic histamine release by the histamine H3 receptor ligands, immepip and clobenpropit. Effects of intrahypothalamic and peripheral application. Eur J Pharmacol 362:149–155
pubmed: 9874165 doi: 10.1016/S0014-2999(98)00739-0
Jáuregui I et al (2016) Bilastine: a new antihistamine with an optimal benefit-to-risk ratio for safety during driving. Expert Opin Drug Saf 15:89–98
pubmed: 26571227 doi: 10.1517/14740338.2016.1112786
Jiang W et al (2008) Cloning and pharmacological characterization of the dog histamine H4 receptor. Eur J Pharmacol 592:26–32
pubmed: 18639542 doi: 10.1016/j.ejphar.2008.06.095
Jochem J, Mitera A, Izydorczyk M, Nowak D, Waliczek M (2016) Cardiovascular effects of histamine H3 receptor antagonist JNJ 5207852 in haemorrhagic shock in rats. Ann Acad Medicae Silesiensis 70:89–94
doi: 10.18794/aams/61176
Jongejan A et al (2005) Linking agonist binding to histamine H1 receptor activation. Nat Chem Biol 1:98–103
pubmed: 16408006 doi: 10.1038/nchembio714
Jutel M, Akdis M, Akdis CA (2009) Histamine, histamine receptors and their role in immune pathology. Clin Exp Allergy 39:1786–1800
pubmed: 20085595 doi: 10.1111/j.1365-2222.2009.03374.x
Kaar SJ, Natesan S, Howes OD (2019) Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology:107704
Kallal L, Benovic JL (2000) Using green fluorescent proteins to study G-protein-coupled receptor localization and trafficking. Trends Pharmacol Sci 21:175–180
pubmed: 10785651 doi: 10.1016/S0165-6147(00)01477-2
Khanfar MA et al (2016) Multiple targeting approaches on histamine H3 receptor antagonists. Front Neurosci 10:1–17
doi: 10.3389/fnins.2016.00201
Kitbunnadaj R et al (2005) N-substituted piperidinyl alkyl imidazoles: discovery of methimepip as a potent and selective histamine H3 receptor agonist. J Med Chem 48:2100–2107
pubmed: 15771452 doi: 10.1021/jm049475h
Koga K et al (2016) Development of TASP0410457 (TASP457), a novel dihydroquinolinone derivative as a PET radioligand for central histamine H3 receptors. EJNMMI Res 6:1–14
doi: 10.1186/s13550-016-0170-2
Kollmeier AP et al (2018) Phase 2a, randomized, double-blind, placebo-controlled, multicentre, parallel-group study of an H4R-antagonist (JNJ-39758979) in adults with uncontrolled asthma. Clin Exp Allergy 48:957–969
pubmed: 29682796 doi: 10.1111/cea.13154
Komater VA et al (2003) H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization. Psychopharmacology (Berl) 167(4):363–372. https://doi.org/10.1007/s00213-003-1431-0
doi: 10.1007/s00213-003-1431-0
Kraus A et al (2009) NG-acylated aminothiazolylpropylguanidines as potent and selective histamine H2 receptor agonists. ChemMedChem 4:232–240
pubmed: 19072936 doi: 10.1002/cmdc.200800296
Kuder K, Kieć-Kononowicz K (2014) Fluorescent GPCR ligands as new tools in pharmacology-update, years 2008- early 2014. Curr Med Chem 21:3962–3975
pubmed: 25174921 doi: 10.2174/0929867321666140826120058
Kuhne S, Wijtmans M, Lim HD, Leurs R, De Esch IJP (2011) Several down, a few to go: histamine H3 receptor ligands making the final push towards the market? Expert Opin Investig Drugs 20:1629–1648
pubmed: 21992603 doi: 10.1517/13543784.2011.625010
Lamb Y, Pitolisant N (2020) A review in narcolepsy with or without cataplexy. CNS Drugs 34:207–218
pubmed: 31997137 doi: 10.1007/s40263-020-00703-x
Lapilla M et al (2011) Histamine regulates autoreactive T cell activation and adhesiveness in inflamed brain microcirculation. J Leukoc Biol 89:259–267
pubmed: 21071626 doi: 10.1189/jlb.0910486
Latorraca NR, Venkatakrishnan AJ, Dror RO (2017) GPCR dynamics: structures in motion. ACS Chem Rev 117:139–155
doi: 10.1021/acs.chemrev.6b00177
Lauritsen K, Laursen LS, Rask-Madsen J (1990) Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (part I). Clin Pharmacokinet 19:11–31
pubmed: 1974182 doi: 10.2165/00003088-199019010-00002
Łażewska D, Kieć-Kononowicz K (2018) Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017). Expert Opin Ther Pat 28:175–196
pubmed: 29334795 doi: 10.1080/13543776.2018.1424135
Łazewska D et al (2009) Diether derivatives of homo- or substituted piperidines as non-imidazole histamine H3 receptor ligands. Bioorg Med Chem 17:3037–3042
pubmed: 19329325 doi: 10.1016/j.bmc.2009.03.014
Lecklin A, Etu-Seppälä P, Stark H, Tuomisto L (1998) Effects of intracerebroventricularly infused histamine and selective H1, H2 and H3 agonists on food and water intake and urine flow in Wistar rats. Brain Res 793:279–288
pubmed: 9630675 doi: 10.1016/S0006-8993(98)00186-3
Leurs R, Church MK, Taglialatela M (2002) H
pubmed: 11972592 doi: 10.1046/j.0954-7894.2002.01314.x
Ligneau X, Garbarg M, Vizuete ML, Diaz J, Purand K, Stark H, Schunack W, Schwartz JC (1994) [1251]Iodoproxyfan, a new antagonist to label and visualize cerebral histamine H3 receptors. J Pharmacol Exp Ther 271(1):452–459
pubmed: 7965746
Ligneau X et al (1998) Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. J Pharmacol Exp Ther 287:658–666
pubmed: 9808693
Ligneau X et al (2007) BF2.649 [1-{3-[3-(4-chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: preclinical pharmacology. J Pharmacol Exp Ther 320:365–375
pubmed: 17005916 doi: 10.1124/jpet.106.111039
Lim HD et al (2005) Evaluation of histamine H1-, H2-, and H 3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H 4 receptor agonist. J Pharmacol Exp Ther 314:1310–1321
pubmed: 15947036 doi: 10.1124/jpet.105.087965
Lin JH (1991) Pharmacokinetic and Pharmacodynamic properties of histamine H2-receptor antagonists: relationship between intrinsic potency and effective plasma concentrations. Clin Pharmacokinet 20:218–236
pubmed: 1673880 doi: 10.2165/00003088-199120030-00004
Lindsay BH, Nalwalk JW, Battles AH (1990) Zolantidine-induced attenuation of morphine antinociception in rhesus monkeys. Brain Res 526:153–155
doi: 10.1016/0006-8993(90)90263-B
Liu H et al (2008) Cis-4-(piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h] quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia. J Med Chem 51:7094–7098
pubmed: 18983139 doi: 10.1021/jm8007618
Logan J et al (2012) Blockade of the brain histamine h3 receptor by jnj-39220675: preclinical pet studies with [11C]gsk189254 in anesthetized baboon. Psychopharmacology (Berl) 223:447–455
doi: 10.1007/s00213-012-2733-x
Ma P, Zemmel R (2002) Value of novelty? Nat Rev Drug Discov 1:571–572
pubmed: 12402497 doi: 10.1038/nrd884
Mackenzie JF, Daly CJ, Pediani JD, McGrath JC (2000) Quantitative imaging in live human cells reveals intracellular α1- adrenoceptor ligand-binding sites. J Pharmacol Exp Ther 294:434–443
pubmed: 10900216
Malmberg-Aiello P, Ipponi A, Bartolini A, Schunack W (2000) Antiamnesic effect of metoprine and of selective histamine H1 receptor agonists in a modified mouse passive avoidance test. Neurosci Lett 288:1–4
pubmed: 10869801 doi: 10.1016/S0304-3940(00)01176-9
Mansbach R (2008) In vitro pharmacological profile of docepin, a sleep-promoting histamine H1 antagonist. Eur Neuropsychopharmacol 18:357–358
doi: 10.1016/S0924-977X(08)70505-4
Martinez-Mir MI et al (1990) Three histamine receptors (H1, H2 and H3) visualized in the brain of human and non-human primates. Brain Res 526:322–327
pubmed: 1979518 doi: 10.1016/0006-8993(90)91240-H
McGaraughty S, Chu KL, Cowart MD, Brioni JD (2012) Antagonism of supraspinal histamine H3 receptors modulates spinal neuronal activity in neuropathic rats. J Pharmacol Exp Ther 343:13–20
pubmed: 22729221 doi: 10.1124/jpet.112.194761
McGrath JC, Arribas S, Daly CJ (1996) Fluorescent ligands for the study of receptors. Trends Pharmacol Sci 17:393–399
pubmed: 8990953 doi: 10.1016/S0165-6147(96)40004-9
Medhurst AD et al (2007) GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer’s disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 321:1032–1045
pubmed: 17327487 doi: 10.1124/jpet.107.120311
Michalet X, Weiss S, Jäger M (2006) Single-molecule fluorescence studies of protein folding and conformational dynamics. Chem Rev 106:1785–1813
pubmed: 16683755 pmcid: 2569857 doi: 10.1021/cr0404343
Miyata I, Saegusa H, Sakurai M (2011) Seizure-modifying potential of histamine H 1 antagonists: a clinical observation. Pediatr Int 53:706–708
pubmed: 21261789 doi: 10.1111/j.1442-200X.2011.03328.x
Mochizuki T et al (1996) Brain penetration of the histamine H3 receptor antagonists thioperamide and clobenpropit in rat and mouse, determined with ex vivo [125I]iodophenpropit binding. Brain Res 743:178–183
pubmed: 9017245 doi: 10.1016/S0006-8993(96)01040-2
Monti JM, Orellana C, Boussard M, Jantos H, Olivera S (1990) Sleep variables are unaltered by zolantidine in rats: are histamine H2-receptors not involved in sleep regulation? Brain Res Bull 25:229–231
pubmed: 1977498 doi: 10.1016/0361-9230(90)90065-8
Morisset S, Traiffort E, Arrang JM, Schwartz JC (2000) Changes in histamine H3 receptor responsiveness in mouse brain. J Neurochem 74:339–346
pubmed: 10617138 doi: 10.1046/j.1471-4159.2000.0740339.x
Mowbray CE et al (2011) Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist. Bioorg Med Chem Lett 21:6596–6602
pubmed: 21920751 doi: 10.1016/j.bmcl.2011.07.125
Murata Y et al (2015) Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis. J Dermatol 42:129–139
pubmed: 25491792 doi: 10.1111/1346-8138.12726
Neumann D et al (2013) The dual H3/4R antagonist thioperamide does not fully mimic the effects of the ‘standard’ H4R antagonist JNJ 7777120 in experimental murine asthma. Naunyn Schmiedebergs Arch Pharmacol 386:983–990
pubmed: 23820873 doi: 10.1007/s00210-013-0898-4
Neumann D, Schneider EH, Seifert R (2014) Analysis of histamine receptor knockout mice in models of inflammation. J Pharmacol Exp Ther 348:2–11
pubmed: 24101735 doi: 10.1124/jpet.113.204214
Nieto-Alamilla G, Marquez-Gomez R, Arias-Montano J-A (2016) The histamine H3 receptor: structure, pharmacology, and function. Mol Pharmacol 90:649–673
pubmed: 27563055 doi: 10.1124/mol.116.104752
Nirogi R et al (2019) Discovery and development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): a novel, potent, selective, and orally active histamine H 3 receptor inverse agonist with robust wake-promoting activity. J Med Chem 62:1203–1217
pubmed: 30629436 doi: 10.1021/acs.jmedchem.8b01280
Nirogi R et al (2021) Samelisant (SUVN-G3031), a potent, selective and orally active histamine H3 receptor inverse agonist for the potential treatment of narcolepsy: pharmacological and neurochemical characterisation. Psychopharmacology (Berl) 1
Nuutinen S et al (2016) Histamine H3 receptor antagonist decreases cue-induced alcohol reinstatement in mice. Neuropharmacology 106:156–163
pubmed: 26107118 doi: 10.1016/j.neuropharm.2015.06.006
Obara I et al (2019) Histamine, histamine receptors, and neuropathic pain relief. Br J Pharmacol 177:580–599
pubmed: 31046146 pmcid: 7012972 doi: 10.1111/bph.14696
Ogasawara M et al (2006) Recent advances in molecular pharmacology of the histamine systems: organic cation transporters as a histamine transporter and histamine metabolism. J Pharmacol Sci 101:24–30
pubmed: 16648665 doi: 10.1254/jphs.FMJ06001X6
Panula P (2020) Histamine, histamine H3 receptor, and alcohol use disorder. Br J Pharmacol 177:634–641
pubmed: 30801695 doi: 10.1111/bph.14634
Panula P et al (2015) International union of basic and clinical pharmacology. XCVIII histamine receptors. Pharmacol Rev 67:601–655
pubmed: 26084539 pmcid: 4485016 doi: 10.1124/pr.114.010249
Parsons ME, Ganellin CR (2006) Histamine and its receptors. Br J Pharmacol 147:127–135
doi: 10.1038/sj.bjp.0706440
Petremann M, Gueguen C, Delgado Betancourt V, Wersinger E, Dyhrfjeld-Johnsen J (2020) Effect of the novel histamine H4 receptor antagonist SENS-111 on spontaneous nystagmus in a rat model of acute unilateral vestibular loss. Br J Pharmacol 177:623–633
pubmed: 31347148 doi: 10.1111/bph.14803
Plisson C et al (2009) 11C-GSK189254: a selective radioligand for in vivo central nervous system imaging of histamine H3 receptors by PET. J Nucl Med 50:2064–2072
pubmed: 19910432 doi: 10.2967/jnumed.109.062919
Proschak E, Stark H, Merk D (2019) Polypharmacology by design: a medicinal Chemist’s perspective on multitargeting compounds. J Med Chem 62:420–444
pubmed: 30035545 doi: 10.1021/acs.jmedchem.8b00760
Provensi G, Costa A, Passani MB, Blandina P (2016) Donepezil, an acetylcholine esterase inhibitor, and ABT-239, a histamine H3 receptor antagonist/inverse agonist, require the integrity of brain histamine system to exert biochemical and procognitive effects in the mouse. Neuropharmacology 109:139–147
pubmed: 27291828 doi: 10.1016/j.neuropharm.2016.06.010
Ramírez FJ, Tuñón I, Collado JA, Silla E (2003) Structural and vibrational study of the tautomerism of histamine free-base in solution. J Am Chem Soc 125:2328–2340
pubmed: 12590563 doi: 10.1021/ja027103x
Reiner D, Stark H (2019) Ligand binding kinetics at histamine H3 receptors by fluorescence-polarization with real-time monitoring. Eur J Pharmacol 848:112–120
pubmed: 30703360 doi: 10.1016/j.ejphar.2019.01.041
Reiner D et al (2020) Epigenetics meets GPCR: inhibition of histone H3 methyltransferase (G9a) and histamine H3 receptor for Prader–Willi syndrome. Sci Rep 10:1–8
doi: 10.1038/s41598-020-70523-y
Reznikov LR et al (2021) Identification of antiviral antihistamines for COVID-19 repurposing. Biochem Biophys Res Commun 538:173–179
pubmed: 33309272 doi: 10.1016/j.bbrc.2020.11.095
Riddy DM et al (2019) Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H 3 receptor antagonists. Neuropharmacology 144:244–255
pubmed: 30359639 doi: 10.1016/j.neuropharm.2018.10.028
Romigi A, Vitrani G, Franco V (2018) Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy. Drug Des Devel Ther 12:2665–2675
pubmed: 30214155 pmcid: 6124464 doi: 10.2147/DDDT.S101145
Rose RH, Briddon SJ, Hill SJ (2012) A novel fluorescent histamine H 1 receptor antagonist demonstrates the advantage of using fluorescence correlation spectroscopy to study the binding of lipophilic ligands. Br J Pharmacol 165:1789–1800
pubmed: 21880035 pmcid: 3372830 doi: 10.1111/j.1476-5381.2011.01640.x
Rosethorne EM, Charlton SJ (2011) Agonist-biased signaling at the histamine H4 receptor: JNJ7777120 recruits β-arrestin without activating G proteins. Mol Pharmacol 79:749–757
pubmed: 21134907 doi: 10.1124/mol.110.068395
Roßbach K et al (2009) The histamine H4 receptor as a new target for treatment of canine inflammatory skin diseases. Vet Dermatol 20:555–561
pubmed: 20178494 doi: 10.1111/j.1365-3164.2009.00854.x
Rossbach K et al (2016) Histamine H4 receptor knockout mice display reduced inflammation in a chronic model of atopic dermatitis. Allergy Eur J Allergy Clin Immunol 71:189–197
doi: 10.1111/all.12779
Rouleau A et al (1997) Bioavailability, antinociceptive and antiinflammatory properties of BP 2-94, a histamine H 3 receptor agonist prodrug. J Pharmacol Exp Ther 281:1085–1094
pubmed: 9190840
Rouleau A, Stark H, Schunack W, Schwartz JC (2000) Anti-inflammatory and antinociceptive properties of BP 2-94, a histamine H3-receptor agonist prodrug. J Pharmacol Exp Ther 295
Rusjan P et al (2020) Exploring occupancy of the histamine H3 receptor by pitolisant in humans using PET. Br J Pharmacol 177:3464–3472
pubmed: 32293706 pmcid: 7348085 doi: 10.1111/bph.15067
Sadek B, Stark H (2016) Cherry-picked ligands at histamine receptor subtypes. Neuropharmacology 106:56–73
pubmed: 26581501 doi: 10.1016/j.neuropharm.2015.11.005
Sadek B et al (2014) Non-imidazole histamine H3 receptor ligands incorporating antiepileptic moieties. Eur J Med Chem 77:269–279
pubmed: 24650714 doi: 10.1016/j.ejmech.2014.03.014
Sadek B et al (2016a) Histamine H3 receptor as a potential target for cognitive symptoms in neuropsychiatric diseases. Behav Brain Res 312:415–430
pubmed: 27363923 doi: 10.1016/j.bbr.2016.06.051
Sadek B et al (2016b) Anticonvulsant and procognitive properties of the non-imidazole histamine H3 receptor antagonist DL77 in male adult rats. Neuropharmacology 106:46–55
pubmed: 26525191 doi: 10.1016/j.neuropharm.2015.10.023
Sander K, Kottke T, Stark H (2008) Histamine H3 receptor antagonists go to clinics. Biol Pharm Bull 31:2163–2181
pubmed: 19043195 doi: 10.1248/bpb.31.2163
Sander K et al (2009) 2,4-Diaminopyrimidines as histamine H4 receptor ligands-scaffold optimization and pharmacological characterization. Bioorg Med Chem 17:7186–7196
pubmed: 19773175 doi: 10.1016/j.bmc.2009.08.059
Sanna MD et al (2017) Histamine H4 receptor agonist-induced relief from painful peripheral neuropathy is mediated by inhibition of spinal neuroinflammation and oxidative stress. Br J Pharmacol 174:28–40
pubmed: 27714773 doi: 10.1111/bph.13644
Saravanan C, Bharti SK, Jaggi S, Singh SK (2011) Histamine H4 receptor: a novel target for inflammation therapy. Mini-Reviews Med Chem 11:143–158
doi: 10.2174/138955711794519519
Sato H et al (2013) Histamine H1 receptor occupancy by the new-generation antidepressants fluvoxamine and mirtazapine: a positron emission tomography study in healthy volunteers. Psychopharmacology (Berl) 230:227–234
doi: 10.1007/s00213-013-3146-1
Schneider EH, Seifert R (2016) The histamine H4-receptor and the central and peripheral nervous system: a critical analysis of the literature. Neuropharmacology 106:116–128
pubmed: 25986697 doi: 10.1016/j.neuropharm.2015.05.004
Schneider EH, Neumann D, Seifert R (2014) Modulation of behavior by the histaminergic system: lessons from H1R-and H2R-deficient mice. Neurosci Biobehav Rev 42:252–266
pubmed: 24661982 doi: 10.1016/j.neubiorev.2014.03.009
Schnell D et al (2011) Expression and functional properties of canine, rat, and murine histamine H4 receptors in Sf9 insect cells. Naunyn Schmiedebergs Arch Pharmacol 383:457–470
pubmed: 21359967 doi: 10.1007/s00210-011-0612-3
Schumacher S, Kietzmann M, Stark H, Bäumer W (2014) Unique immunomodulatory effects of azelastine on dendritic cells in vitro. Naunyn Schmiedebergs Arch Pharmacol 387:1091–1099
pubmed: 25119779 doi: 10.1007/s00210-014-1033-x
Schwartz JC (2011) The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol 163:713–721
pubmed: 21615387 pmcid: 3111674 doi: 10.1111/j.1476-5381.2011.01286.x
Seifert R et al (2003) Multiple differences in agonist and antagonist pharmacology between human and guinea pig histamine H1-receptor. J Pharmacol Exp Ther 305:1104–1115
pubmed: 12626648 doi: 10.1124/jpet.103.049619
Seifert R, Schneider EH, Dove S, Brunskole I, Neumann D, Strasser A, Buschauer A (2011) Paradoxical stimulatory effects of the “Standard” histamine H4-receptor antagonist JNJ7777120: the H4 receptor joins the club of 7 transmembrane domain receptors exhibiting functional selectivity. Naunyn Schmiedebergs Arch Pharmacol 383:457–470
pubmed: 21359967
Selivanova SV et al (2012) Radiofluorinated histamine H 3 receptor antagonist as a potential probe for in vivo PET imaging: Radiosynthesis and pharmacological evaluation. Bioorg Med Chem 20:2889–2896
pubmed: 22483590 doi: 10.1016/j.bmc.2012.03.024
Shahid M et al (2009) Histamine, histamine receptors, and their role in immunomodulation: an updated systematic review. Open Immunol J 2:9–41
doi: 10.2174/1874226200902010009
Shi Y et al (2012) Identification and characterization of ZEL-H16 as a novel agonist of the histamine H3 receptor. PLoS One 7
Shimamura T et al (2011) Structure of the human histamine H 1 receptor complex with doxepin. Nature 475:65–72
pubmed: 21697825 pmcid: 3131495 doi: 10.1038/nature10236
Shin N et al (2012) INCB38579, a novel and potent histamine H 4 receptor small molecule antagonist with anti-inflammatory pain and anti-pruritic functions. Eur J Pharmacol 675:47–56
pubmed: 22155710 doi: 10.1016/j.ejphar.2011.11.027
Simons FER, Simons KJ (2011) Histamine and H1-antihistamines: celebrating a century of progress. J Allergy Clin Immunol 128
Slack RJ et al (2011) Pharmacological characterization of GSK1004723, a novel, long-acting antagonist at histamine H 1 and H 3 receptors. Br J Pharmacol 164:1627–1641
pubmed: 22022805 pmcid: 3230810 doi: 10.1111/j.1476-5381.2011.01285.x
Slamet Soetanto T et al (2019) Histamine uptake mediated by plasma membrane monoamine transporter and organic cation transporters in rat mast cell lines. Eur J Pharmacol 849:75–83
pubmed: 30707958 doi: 10.1016/j.ejphar.2019.01.050
Smits RA et al (2008) Fragment based design of new H4 receptor-ligands with anti-inflammatory properties in vivo. J Med Chem 51:2457–2467
pubmed: 18357976 doi: 10.1021/jm7014217
Stark H (2020) The chemical probe–scopes, limitations and challenges. Expert Opin Drug Discovery 15:1365–1367
doi: 10.1080/17460441.2020.1781086
Stark H et al (1996) [125I]lodoproxyfan and related compounds: a reversible radioligand and novel classes of antagonists with high affinity and selectivity for the histamine H3 receptor. J Med Chem 39:1220–1226
pubmed: 8632428 doi: 10.1021/jm9504767
Sugimoto Y, Umakoshi K, Nojiri N, Kamei C (1998) Effects of histamine H1 receptor antagonists on compound 48/80-induced scratching behavior in mice. Eur J Pharmacol 351:1–5
pubmed: 9698198 doi: 10.1016/S0014-2999(98)00288-X
Syed YY (2016) Pitolisant: first global approval. Drugs 76:1313–1318
pubmed: 27438291 doi: 10.1007/s40265-016-0620-1
Szczepańska K et al (2018) Synthesis and biological activity of novel tert-butyl and tert-pentylphenoxyalkyl piperazine derivatives as histamine H3R ligands. Eur J Med Chem 152:223–234
pubmed: 29723785 doi: 10.1016/j.ejmech.2018.04.043
Taha AS et al (1996) Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 334:1435–1439
pubmed: 8618582 doi: 10.1056/NEJM199605303342204
Tashiro M et al (2002) Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain. Life Sci 72:409–414
pubmed: 12467881 doi: 10.1016/S0024-3205(02)02276-2
Thurmond RL (2015) The histamine H4 receptor: from orphan to the clinic. Front Pharmacol 6:1–11
doi: 10.3389/fphar.2015.00065
Thurmond RL et al (2004) A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther 309:404–413
pubmed: 14722321 doi: 10.1124/jpet.103.061754
Thurmond RL et al (2014) Clinical and preclinical characterization of the histamine H4 receptor antagonist JNJ-39758979s. J Pharmacol Exp Ther 349:176–184
pubmed: 24549371 doi: 10.1124/jpet.113.211714
Thurmond RL et al (2016) Toreforant, a histamine H4 receptor antagonist, in patients with active rheumatoid arthritis despite methotrexate therapy: results of 2 phase II studies. J Rheumatol 43:1637–1642
pubmed: 27422891 doi: 10.3899/jrheum.160164
Tichenor MS, Thurmond RL, Venable JD, Savall BM (2015) Functional profiling of 2-aminopyrimidine histamine H4 receptor modulators. J Med Chem 58:7119–7127
pubmed: 25993395 doi: 10.1021/acs.jmedchem.5b00516
Tiligada E, Ennis M (2020) Histamine pharmacology: from Sir Henry Dale to the 21st century. Br J Pharmacol 177:469–489
pubmed: 30341770 doi: 10.1111/bph.14524
Tiligada E, Zampeli E, Sander K, Stark H (2009) Histamine H3 and H4 receptors as novel drug targets. Expert Opin Investig Drugs 18:1519–1531
pubmed: 19758107 doi: 10.1517/14728220903188438
Tomasch M, Schwed JS, Stark H (2013) Bodilisant-a novel fluorescent, highly affine histamine h3 receptor ligand. ACS Med Chem Lett 4:269–273
pubmed: 24900647 doi: 10.1021/ml300383n
Tripathi T et al (2010) In vivo comparative immunotoxic study of histamine receptors (H1R, H2R, H3R and H4R)-agonist. East J Med 15:48–56
Uguen M et al (2013) Preclinical evaluation of the abuse potential of Pitolisant, a histamine H3 receptor inverse agonist/antagonist compared with Modafinil. Br J Pharmacol 169:632–644
pubmed: 23472741 pmcid: 3682710 doi: 10.1111/bph.12149
Van Der Goot H, Timmerman H (2000) Selective ligands as tools to study histamine receptors. Eur J Med Chem 35:5–20
pubmed: 10733599 doi: 10.1016/S0223-5234(00)00101-X
Varaschin RK, Akers KG, Rosenberg MJ, Hamilton DA, Savage DD (2010) Effects of the cognition-enhancing agent ABT-239 on fetal ethanol-induced deficits in dentate gyrus synaptic plasticity. J Pharmacol Exp Ther 334:191–198
pubmed: 20308329 pmcid: 2912053 doi: 10.1124/jpet.109.165027
Varga C et al (2005) Inhibitory effects of histamine H4 receptor antagonists on experimental colitis in the rat. Eur J Pharmacol 522:130–138
pubmed: 16213481 doi: 10.1016/j.ejphar.2005.08.045
Venable J, Thurmond R (2012) Development and chemistry of histamine H4 receptor ligands as potential modulators of inflammatory and allergic responses. Antiinflamm Antiallergy Agents Med Chem 5:307–322
doi: 10.2174/187152306778772801
Venail F et al (2018) Safety, tolerability, pharmacokinetics and pharmacokinetic-pharmacodynamic modelling of the novel H4 receptor inhibitor SENS-111 using a modified caloric test in healthy subjects. Br J Clin Pharmacol 84:2836–2848
pubmed: 30152527 pmcid: 6255991 doi: 10.1111/bcp.13744
Venkatachalam K, Eissa N et al (2021) The histamine H3R and dopamine D2R/D3R antagonist ST-713 ameliorates autism-like behavioral features in BTBR T + tf/J mice by multiple actions. Biomed Pharmacother 138
Wagner E, Wittmann HJ, Elz S, Strasser A (2011) Mepyramine-JNJ7777120-hybrid compounds show high affinity to hH 1R, but low affinity to hH4R. Bioorg Med Chem Lett 21:6274–6280
pubmed: 21944853 doi: 10.1016/j.bmcl.2011.09.001
Walter M et al (2010) Azole derivatives as histamine H3 receptor antagonists, part I: thiazol-2-yl ethers. Bioorg Med Chem Lett 20:5879–5882
pubmed: 20728354 doi: 10.1016/j.bmcl.2010.07.098
Wang J et al (2021) Pitolisant versus placebo for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: a meta-analysis from randomized controlled trials. Pharmacol Res:105522. https://doi.org/10.1016/j.phrs.2021.105522
Werfel T et al (2016) Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol 138:336–349
pubmed: 27497276 doi: 10.1016/j.jaci.2016.06.010
Werfel T et al (2019) Efficacy and safety of the histamine H 4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis. J Allergy Clin Immunol 143
Windhorst AD et al (1999) Evaluation of [18F]VUF 5000 as a potential PET ligand for brain imaging of the histamine H3 receptor. Bioorg Med Chem 7:1761–1767
pubmed: 10530922 doi: 10.1016/S0968-0896(99)00108-X
Wyllie JH, Hesselbo T, Black JW (1972) Effects in man of histamine H2-receptor blockade by burimamide. Lancet:1117–1120
Xie SX, Ghorai P, Ye QZ, Buschauer A, Seifert R (2006) Probing ligand-specific histamine H1- and H2-receptor conformations with NG-acylated imidazolylpropylguanidines. J Pharmacol Exp Ther 317:139–146
pubmed: 16394198 doi: 10.1124/jpet.105.097923
Yanai K et al (1992a) Mapping of histamine H1 receptors in the human brain using [11C]Pyrilamine and positron emission tomography. J Neurochem 59:128–136
pubmed: 1613494 doi: 10.1111/j.1471-4159.1992.tb08883.x
Yanai K et al (1992b) Histamine H1 receptors in human brain visualized in vivo by [11C]doxepin and positron emission tomography. Neurosci Lett 137:145–148
pubmed: 1584454 doi: 10.1016/0304-3940(92)90390-S
Yanai K et al (1995) Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography. Br J Pharmacol 116:1649–1655
pubmed: 8564232 pmcid: 1908925 doi: 10.1111/j.1476-5381.1995.tb16386.x
Yanai K et al (2011) Positron emission tomography evaluation of sedative properties of antihistamines. Expert Opin Drug Saf 10:613–622
pubmed: 21521134 doi: 10.1517/14740338.2011.562889
Yoshimoto R et al (2006) Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus. Proc Natl Acad Sci U S A 103:13866–13871
pubmed: 16954192 pmcid: 1560086 doi: 10.1073/pnas.0506104103
Zhang YF, Chen XY, Zhong DF, Dong YM (2003) Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects. Acta Pharmacol Sin 24:715–718. 727
pubmed: 12852841
Zhao C et al (2008) The alkaloid conessine and analogues as potent histamine H3 receptor antagonists. J Med Chem 51:5423–5430
pubmed: 18683917 doi: 10.1021/jm8003625
Zhou Y, Offord S, Dogan AS, Crabb AH, Wong DF (2002) Evaluation of antihistamine drugs by human [11C]doxepin dynamic PET studies with a parametric image approach. IEEE Nucl Sci Symp Med Imaging Conf 2:1085–1091
Zhou Y et al (2018) Exploring halogen bonds in 5-hydroxytryptamine 2B receptor-ligand interactions. ACS Med Chem Lett 9:1019–1024
pubmed: 30344910 pmcid: 6187415 doi: 10.1021/acsmedchemlett.8b00300

Auteurs

Markus Falkenstein (M)

Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Duesseldorf, Germany.

Milica Elek (M)

Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Duesseldorf, Germany.

Holger Stark (H)

Institute of Pharmaceutical and Medicinal Chemistry, Heinrich Heine University Düsseldorf, Duesseldorf, Germany. stark@hhu.de.

Articles similaires

A head-to-head comparison of MM/PBSA and MM/GBSA in predicting binding affinities for the CB

Mei Qian Yau, Clarence W Y Liew, Jing Hen Toh et al.
1.00
Receptor, Cannabinoid, CB1 Ligands Molecular Dynamics Simulation Protein Binding Thermodynamics

BASE: a web service for providing compound-protein binding affinity prediction datasets with reduced similarity bias.

Hyojin Son, Sechan Lee, Jaeuk Kim et al.
1.00
Proteins Protein Binding Ligands Internet Databases, Protein

Eosinophilic cationic protein and D-Dimer are potential biomarkers to predict response to antihistamines but not to omalizumab in chronic spontaneous urticaria.

Özge Atik, Fatma Merve Tepetam, Şeyma Özden et al.
1.00
Humans Omalizumab Female Male Chronic Urticaria

Histamine stimulates human microglia to alter cellular prion protein expression via the HRH2 histamine receptor.

Marcus Pehar, Melissa Hewitt, Ashley Wagner et al.
1.00
Humans Microglia Histamine Cell Line Receptors, Histamine H2

Classifications MeSH

questionsmedicales.fr › Facteurs biologiques › Médiateurs de l'inflammation › Autacoïdes › Histamine › Chemical Probes for Histamine Receptor Subtypes.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents histaminiques › Antihistaminiques › Chemical Probes for Histamine Receptor Subtypes.
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Ligands › Chemical Probes for Histamine Receptor Subtypes.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs histaminergiques › Chemical Probes for Histamine Receptor Subtypes.